Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study

David Marrero, Yong Ma, Mary de Groot, Edward S. Horton, David W. Price, Elizabeth Barrett-Connor, Mercedes R. Carnethon, William C. Knowler

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To assess in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study whether diagnosis of diabetes predicted elevated depressive symptoms (DS) or use of antidepressant medicine (ADM) following diagnosis; whether diabetes status or duration had significant effect on DS or ADMuse; and to determine the associations between A1C, fasting plasma glucose (FPG), normalization of FPG, and DS or ADM use after diagnosis. Methods: Diabetes Prevention Program participants in three treatment arms (intensive life style, metformin, placebo) were assessed for diabetes, glucose control,ADMuse, and DS,measured using the Beck Depression Inventory (BDI). Among 3234 participants, 1285 developed diabetes. Depression levels were measured before and after diabetes diagnosis. Results: Neither DS nor use of ADM increased after diagnosis; higher FPG was associated with greater ADM use in the intensive life style arm; a 10-mg/dl rise in FPG is associated with greater odds of ADM use. Higher FPG and A1C were associated with higher BDI scores in all three arms; A 10-mg/dl rise in FPG had a 0.07 increase in BDI. A 1% higher A1c was associated with a 0.21-point increase in BDI. Normalization of FPG was associated with lower BDI.When FPG had normalized, there was a decrease of 0.30 points in the BDI score compared when FPG had not normalized. Conclusions: Contrary to clinical attributions, diabetes diagnosis did not show an immediate impact on BDI scores or ADM use. Higher glucose levels after diagnosis were associated with a small but significantly higher BDI score and more ADM use. Trial Registration: DPPOS: NCT00038727; DPP: NCT00004992.

Original languageEnglish
Pages (from-to)303-310
Number of pages8
JournalPsychosomatic Medicine
Volume77
Issue number3
DOIs
StatePublished - Apr 15 2015

Fingerprint

Antidepressive Agents
Outcome Assessment (Health Care)
Depression
Fasting
Glucose
Medicine
Equipment and Supplies
Onset
Diabetes
Medication
Antidepressants
Plasma
Depressive Symptoms
Life Style
Metformin
Placebos

Keywords

  • antidepressant medication
  • depressive symptoms
  • diagnosis of diabetes
  • prediabetes
  • Type 2 diabetes mellitus, prevenion

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Applied Psychology
  • Arts and Humanities (miscellaneous)
  • Developmental and Educational Psychology

Cite this

Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study. / Marrero, David; Ma, Yong; de Groot, Mary; Horton, Edward S.; Price, David W.; Barrett-Connor, Elizabeth; Carnethon, Mercedes R.; Knowler, William C.

In: Psychosomatic Medicine, Vol. 77, No. 3, 15.04.2015, p. 303-310.

Research output: Contribution to journalArticle

Marrero, David ; Ma, Yong ; de Groot, Mary ; Horton, Edward S. ; Price, David W. ; Barrett-Connor, Elizabeth ; Carnethon, Mercedes R. ; Knowler, William C. / Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study. In: Psychosomatic Medicine. 2015 ; Vol. 77, No. 3. pp. 303-310.
@article{5eb4a4c179914647b3640f3fa53c7e72,
title = "Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study",
abstract = "Objective: To assess in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study whether diagnosis of diabetes predicted elevated depressive symptoms (DS) or use of antidepressant medicine (ADM) following diagnosis; whether diabetes status or duration had significant effect on DS or ADMuse; and to determine the associations between A1C, fasting plasma glucose (FPG), normalization of FPG, and DS or ADM use after diagnosis. Methods: Diabetes Prevention Program participants in three treatment arms (intensive life style, metformin, placebo) were assessed for diabetes, glucose control,ADMuse, and DS,measured using the Beck Depression Inventory (BDI). Among 3234 participants, 1285 developed diabetes. Depression levels were measured before and after diabetes diagnosis. Results: Neither DS nor use of ADM increased after diagnosis; higher FPG was associated with greater ADM use in the intensive life style arm; a 10-mg/dl rise in FPG is associated with greater odds of ADM use. Higher FPG and A1C were associated with higher BDI scores in all three arms; A 10-mg/dl rise in FPG had a 0.07 increase in BDI. A 1{\%} higher A1c was associated with a 0.21-point increase in BDI. Normalization of FPG was associated with lower BDI.When FPG had normalized, there was a decrease of 0.30 points in the BDI score compared when FPG had not normalized. Conclusions: Contrary to clinical attributions, diabetes diagnosis did not show an immediate impact on BDI scores or ADM use. Higher glucose levels after diagnosis were associated with a small but significantly higher BDI score and more ADM use. Trial Registration: DPPOS: NCT00038727; DPP: NCT00004992.",
keywords = "antidepressant medication, depressive symptoms, diagnosis of diabetes, prediabetes, Type 2 diabetes mellitus, prevenion",
author = "David Marrero and Yong Ma and {de Groot}, Mary and Horton, {Edward S.} and Price, {David W.} and Elizabeth Barrett-Connor and Carnethon, {Mercedes R.} and Knowler, {William C.}",
year = "2015",
month = "4",
day = "15",
doi = "10.1097/PSY.0000000000000156",
language = "English",
volume = "77",
pages = "303--310",
journal = "Psychosomatic Medicine",
issn = "0033-3174",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study

AU - Marrero, David

AU - Ma, Yong

AU - de Groot, Mary

AU - Horton, Edward S.

AU - Price, David W.

AU - Barrett-Connor, Elizabeth

AU - Carnethon, Mercedes R.

AU - Knowler, William C.

PY - 2015/4/15

Y1 - 2015/4/15

N2 - Objective: To assess in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study whether diagnosis of diabetes predicted elevated depressive symptoms (DS) or use of antidepressant medicine (ADM) following diagnosis; whether diabetes status or duration had significant effect on DS or ADMuse; and to determine the associations between A1C, fasting plasma glucose (FPG), normalization of FPG, and DS or ADM use after diagnosis. Methods: Diabetes Prevention Program participants in three treatment arms (intensive life style, metformin, placebo) were assessed for diabetes, glucose control,ADMuse, and DS,measured using the Beck Depression Inventory (BDI). Among 3234 participants, 1285 developed diabetes. Depression levels were measured before and after diabetes diagnosis. Results: Neither DS nor use of ADM increased after diagnosis; higher FPG was associated with greater ADM use in the intensive life style arm; a 10-mg/dl rise in FPG is associated with greater odds of ADM use. Higher FPG and A1C were associated with higher BDI scores in all three arms; A 10-mg/dl rise in FPG had a 0.07 increase in BDI. A 1% higher A1c was associated with a 0.21-point increase in BDI. Normalization of FPG was associated with lower BDI.When FPG had normalized, there was a decrease of 0.30 points in the BDI score compared when FPG had not normalized. Conclusions: Contrary to clinical attributions, diabetes diagnosis did not show an immediate impact on BDI scores or ADM use. Higher glucose levels after diagnosis were associated with a small but significantly higher BDI score and more ADM use. Trial Registration: DPPOS: NCT00038727; DPP: NCT00004992.

AB - Objective: To assess in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study whether diagnosis of diabetes predicted elevated depressive symptoms (DS) or use of antidepressant medicine (ADM) following diagnosis; whether diabetes status or duration had significant effect on DS or ADMuse; and to determine the associations between A1C, fasting plasma glucose (FPG), normalization of FPG, and DS or ADM use after diagnosis. Methods: Diabetes Prevention Program participants in three treatment arms (intensive life style, metformin, placebo) were assessed for diabetes, glucose control,ADMuse, and DS,measured using the Beck Depression Inventory (BDI). Among 3234 participants, 1285 developed diabetes. Depression levels were measured before and after diabetes diagnosis. Results: Neither DS nor use of ADM increased after diagnosis; higher FPG was associated with greater ADM use in the intensive life style arm; a 10-mg/dl rise in FPG is associated with greater odds of ADM use. Higher FPG and A1C were associated with higher BDI scores in all three arms; A 10-mg/dl rise in FPG had a 0.07 increase in BDI. A 1% higher A1c was associated with a 0.21-point increase in BDI. Normalization of FPG was associated with lower BDI.When FPG had normalized, there was a decrease of 0.30 points in the BDI score compared when FPG had not normalized. Conclusions: Contrary to clinical attributions, diabetes diagnosis did not show an immediate impact on BDI scores or ADM use. Higher glucose levels after diagnosis were associated with a small but significantly higher BDI score and more ADM use. Trial Registration: DPPOS: NCT00038727; DPP: NCT00004992.

KW - antidepressant medication

KW - depressive symptoms

KW - diagnosis of diabetes

KW - prediabetes

KW - Type 2 diabetes mellitus, prevenion

UR - http://www.scopus.com/inward/record.url?scp=84927589736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927589736&partnerID=8YFLogxK

U2 - 10.1097/PSY.0000000000000156

DO - 10.1097/PSY.0000000000000156

M3 - Article

C2 - 25775165

AN - SCOPUS:84927589736

VL - 77

SP - 303

EP - 310

JO - Psychosomatic Medicine

JF - Psychosomatic Medicine

SN - 0033-3174

IS - 3

ER -